Ocuphire Pharma Results Presentation Deck
Patients, %
20
80
60
40
20
0
Historic Data for Diabetic Patients on DR Progression
The Worse the DRSS, the Higher the Risk of Vision Threatening Complications
4.2
9.8
≥3-Step
Worsening
Lucentis data shows that 28% untreated eyes will
worsen DRSS by ≥ 2-steps over 1 year
Stability of DR from Month 36 to month 48
Received Re-treatment
During OLE (n=285)
No Re-treatment
During OLE (n=82)
5.3
18.3
2-Step
Worsening
15.1
13.4
1-Step
Worsening
66.3
54.9
Stable
6.7
2.4
1.1 1.2
1-Step
2-Step
Improvement Improvement
DRSS Change from Month 36 to Month 48
Source - Sun JK, Evidence for Diabetic Retinopathy Progression and Regression from Clinical Trials.
Presented at NDI/FDA DR Clinical Trials Design and Endpoints Workshop, June 26, 2015.
1.4 0
23-Step
Improvement
Cumulative Incidence, %
Probability of developing PDR or DME is greater
with higher baseline NPDR severity
60-
40-
20-
15
Years
Severe nonproliferative diabetic retinopathy (state 4)
Moderate nonproliferative diabetic retinopathy (state 3)
Mild nonproliferative diabetic retinopathy (state 2)
No retinopathy (state 1)
5
10
20
Source - Frequency of Evidence-Based Screening for Retinopathy in
Type 1 Diabetes. N Engl J Med. 2017 Apr 20;376(16):1507-1516. doi:
10.1056/NEJMoa1612836. PMID: 28423305; PMCID: PMC5557280
25
30
OcuphireView entire presentation